Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia

Journal of Clinical Oncology

Volumn 21, Issue 7, 2003, Pages 1332-1339

  Schmiegelow, Kjeld ^a   Björk, Olle ^a   Glomstein, Anders ^a   Gustafsson, Göran ^a   Keiding, Niels ^a   Kristinsson, Jon ^a   Mäkipernaa, Anne ^a   Rosthøj, Susanne ^a   Szumlanski, Carol ^a   Sørensen, Tine M ^a   Weinshilboum, Richard ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE; METHOTREXATE; NUCLEOTIDE DERIVATIVE; THIOGUANINE NUCLEOTIDE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; TIOGUANINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVITY; ERYTHROCYTE; FEMALE; FOLLOW UP; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD; CHEMISTRY; INFANT; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; RECURRENT DISEASE; SEX DIFFERENCE;

6-MERCAPTOPURINE; ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKOCYTE COUNT; MALE; METHOTREXATE; NEUTROPHILS; RECURRENCE; SEX FACTORS; THIOGUANINE;

EID: 0038576296     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.039     Document Type: Article

References (51)

1. Lilleyman JS, Lennard L: Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia. Lancet 343:1188-1190, 1994
2. Schmiegelow K, Schrøder H, Gustafsson G, et al: Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology. J Clin Oncol 13:345-351, 1995
3. Gustafsson G, Schmiegelow K, Forestier E, et al: Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Leukemia 14:2267-2275, 2000
4. Evans WE, Relling MV, Rodman JH, et al: Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499-505, 1998
5. Schmiegelow K, Pulczynska MK: Maintenance chemotherapy for childhood acute lymphoblastic leukemia: Should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol 12:462-467, 1990
6. Waters TR, Swann PF: Cytotoxic mechanism of 6-thioguanine: hMut-Salpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 36:2501-2506, 1997
7. Weinshilboum RM, Otterness DM, Szumlanski CL: Methylation pharmacogenetics: Catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 39:19-52, 1999
8. Leonard L, Lilleyman JS: Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816-1823, 1989
9. Chabner BA, Allegra CJ, Curt GA, et al: Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 76:907-912, 1985
10. Masson E, Relling MV, Synold TW, et al: Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 97:73-80, 1996
11. Bökkerink JP, Bakker MA, Hulscher TW, et al: Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37:2321-2327, 1988
12. Bökkerink JP, Stet EH, De Abreu RA, et al: 6-Mercaptopurine: Cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts. Biochem Pharmacol 45:1455-1463, 1993
13. Schrøder H: Methotrexate pharmacokinetics in age-fractionated erythrocytes. Cancer Chemother Pharmacol 18:203-207, 1986
14. Lennard L, Rees CA, Lilleyman JS, et al: Childhood leukaemia: A relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 16:359-363, 1983
15. Lennard L, Lilleyman JS, Van Loon J, et al: Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 336:225-229, 1990
16. Schmiegelow K, Schrøder H, Schmiegelow M: Methotrexate and 6-mercaptopurine maintenance therapy for childhood acute lymphoblastic leukemia: Dose adjustments by white cell counts or by pharmacokinetic parameters? Cancer Chemother Pharmacol 34:209-215, 1994
17. Bruunshuus I, Schmiegelow K: Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiouric acid in biological fluids by high-performance liquid chromatography. Scand J Clin Lab Invest 49:779-784, 1989
18. Kamen BA, Takach PL, Vatev R, et al: A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 70:54-63, 1976
19. Weinshilboum RM, Raymond FA, Pazmino PA: Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 85:323-333, 1978
20. Siegel S, Castellan NJ: Nonparametric Statistics for the Behavioral Sciences. Singapore, McGraw-Hill, 1988
21. Cox DR: Regression models and life-tables. J R Slat Soc B 34:187-220, 1972
22. Andersen PK, Borgan Ø, Gill RD, et al: Statistical Models Based on Counting Processes. New York, NY, Springer, 1993
23. Lilleyman JS, Lennard L, Rees CA, et al: Childhood lymphoblastic leukaemia: Sex difference in 6-mercaptopurine utilization. Br J Cancer 49:703-707, 1984
24. Kaplan EJ, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
25. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother 50:163-170, 1966
26. SAS Statistical Program. Cary, NC, Statistical Analysis Systems, 2001
27. Thomsen JB, Schrøder H, Kristinsson J, et al: Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism. Cancer 86:1080-1086, 1999
28. Peeters M, Koren G, Jakubovicz D, et al: Physician compliance and relapse rates of acute lymphoblastic leukemia in children. Clin Pharmacol Ther 43:228-232, 1988
29. Lancaster D, Lennard L, Lilleyman JS: Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child 76:365-366, 1997
30. Lanning M, Garwicz S, Hertz H, et al: Superior treatment results in females with high-risk acute lymphoblastic leukemia in childhood. Acta Paediatr 81:66-68, 1992
31. Chessells JM, Richards SM, Bailey CC, et al: Gender and treatment outcome in childhood lymphoblastic leukaemia: Report from the MRC UKALL trials. Br J Haematol 89:364-372, 1995
32. Pui CH, Boyett JM, Relling MV, et al: Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 17:818-824, 1999
33. Bostrom B, Erdmann G: Cellular pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 11:80-86, 1993
34. Relling MV, Hancock ML, Boyett JM, et al: Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia. Blood 93:2817-2823, 2001
35. McLeod HL, Relling MV, Liu Q, et al: Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902, 1995
36. Keuzenkamp-Jansen CW, Leegwater PA, De Abreu RA, et al: Thiopurine methyltransferase: A review and a clinical pilot study. J Chromatogr Biomed Appl 678:15-22, 1996
37. Greaves L, Sinclair D: International register of current randomised protocols in childhood acute lymphoblastic leukemia. Oxford, United Kingdom, ICRF/MRC Clinical Trial Service Unit, 1996
38. Lancaster DL, Lennard L, Rowland K, et al: Thioguanine versus mercaptopurine for therapy of childhood lymphoblastic leukaemia: A comparison of haematological toxicity and drug metabolite concentrations. Br J Haematol 102:439-443, 1998
39. Erb N, Harms DO, Janka-Schaub G: Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 42: 266-272, 1998
40. Janka GE, Harms DO, Graubner U, et al: Randomized comparison of 6-mercaptopurine vs 6-thioguanine in childhood ALL: Differing cytotoxicity and interim results. Med Fed Oncol 31:267, 1998 (abstr)
41. Andersen JB, Szumlanski C, Weinshilboum RM, et al: Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr 87:108-111, 1998
42. Schmiegelow K: Prognostic significance of methotrexate and 6-mercaptopurine dosage during maintenance chemotherapy for childhood acute lymphoblastic leukemia. Pediatr Hematol Oncol 8:301-312, 1991
43. Lennard L, Welch J, Lilleyman JS; Mercaptopurine in childhood leukaemia: The effects of dose escalation on thioguanine nucleotide metabolites. Br J Clin Pharmacol 42: 525-527, 1996
44. Miller DR, Leikin SL, Albo VC, et al: Three versus five years of maintenance therapy are equivalent in childhood acute lymphoblastic leukemia: A report from the Childrens Cancer Study Group. J Clin Oncol 7:316-325, 1989
45. Reiter A, Schrappe M, Ludwig WD, et al: Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 84:3122-3133, 1994
46. Pui CH, Dodge RK, Look AT, et al: Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St. Jude Total Therapy studies VIII, IX, and X. J Clin Oncol 9:1341-1347, 1991
47. Koizumi S, Fujimoto T, Takeda T, et al: Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group. Cancer 61:1292-1300, 1988
48. Veerman AJ, Hahlen K, Kamps WA, et al: High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute-lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 14:911-918, 1996
49. Anonymous: Improvement in treatment for children with acute lymphoblastic leukaemia. The Medical Research Council UKALL trials, 1972-84. Report to the Council by the Working Party on Leukaemia in Childhood. Lancet 1:408-411, 1986
50. Eden OB, Stiller CA, Gerrard MP: Improved survival for childhood acute lymphoblastic leukemia: Possible effect of protocol compliance. Pediatr Hematol Oncol 5:83-91, 1988
51. Mantadakis E, Smith AK, Kamen BA: Ratio of methotrexate to folate uptake by lymphoblasts in children with B-lineage acute lymphoblastic leukemia: A pilot study. J Pediatr Hematol Oncol 22:221-226, 2000